[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alveolar-bone-loss--therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alveolar-bone-loss--therapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100637686","clinical-study-of-bmp-2-injectable-hydrogel-for-promoting-alveolar-bone-regeneration-100637686",false,"NCT07611617","Clinical Study of BMP-2 Injectable Hydrogel for Promoting Alveolar Bone Regeneration","Study on Injectable Hydrogel Loaded With BMP-2 for Promoting Alveolar Bone Regeneration Induced by Periodontitis","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n* Compliance and Consent: The subject is able to understand the study procedures, voluntarily sign the informed consent form, and commit to returning for follow-up visits as required (1, 3, 6, 12 months).\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women.","ALL","18 Years","70 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","This project aims to construct an injectable self-healing hydrogel loaded with BMP-2, with optimized gelation time and mechanical strength to meet the requirements for periodontal pocket filling, for the treatment of periodontitis and acceleration of tissue repair, achieving a \"bactericidal-anti-inflammatory-regenerative\" trinity function. This project will provide a novel intelligent material for promoting alveolar bone regeneration in periodontitis and establish a theoretical paradigm for the precise intervention of oral infectious diseases.",[27,28],"Periodontitis","Alveolar Bone Loss* \u002F Therapy",[27,30,31,32],"Alveolar Bone Loss* \u002F therapy","BMP-2","Hydrogel","NOT_YET_RECRUITING","2026-05-20",{"date":36,"type":37},"2026-05-28","ACTUAL",{"date":39,"type":21},"2026-05-01",{"date":41,"type":21},"2028-12-31",{"name":43,"class":44},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":65,"leadSponsor":66,"locationsCount":4},"100639168","study-on-silk-fibroin-reinforced-collagen-based-composite-membrane-for-periodontal-bone-tissue-regeneration-100639168","NCT07574853","Study on Silk Fibroin-Reinforced Collagen-Based Composite Membrane for Periodontal Bone Tissue Regeneration","Clinical Study of Silk Fibroin-Reinforced Collagen-Based Composite Membrane for Promoting Alveolar Bone Regeneration","Inclusion Criteria:\n\n* Clinical Diagnosis: Meets the 2018 International Classification of Periodontal Diseases, diagnosed with Stage III or IV periodontitis.\n* Bone Defect Characteristics: At least one affected tooth presents with a deep periodontal pocket (PPD ≥5 mm), and CBCT imaging confirms the presence of significant vertical bone resorption or angular bone defects (these defect types are most suitable for in-situ hydrogel filling and guided regeneration).\n* Age and General Condition: Aged between 18 and 70 years, any gender, generally in good systemic health.\n* Compliance and Consent: The subject is able to understand the study procedures, voluntarily sign the informed consent form, and commit to returning for follow-up visits as required (1, 3, 6, 12 months).\n\nExclusion Criteria:\n\n* Systemic Interference with Bone Metabolism: Presence of poorly controlled diabetes (HbA1c \\> 7%), osteoporosis, or long-term use of medications affecting bone metabolism such as bisphosphonates or glucocorticoids within the past six months.\n* Local Anatomical Limitations: The affected tooth has a vertical root fracture, severe periapical pathology, or a residual root that is deemed non-restorable and without preservation value.\n* Factors Interfering with Healing: Heavy smokers (average \\> 10 cigarettes per day), as impaired microcirculation can significantly compromise the biological effects of the hydrogel.\n* Special Physiological Periods: Pregnant or breastfeeding women. Drug Allergy: Known allergy to minocycline (MH), hyaluronic acid (HA), or similar chemical components.",{"count":20,"type":21},[24],"Based on the mechanism of intramembranous ossification of the alveolar bone, it is necessary to design a biomimetic membrane material based on the principle of GBR (Guided Bone Regeneration) to simulate the biological microenvironment of alveolar bone regeneration, promote the direct differentiation of stem cells into osteoblasts and rapid mineralization, thereby achieving the goal of alveolar bone regeneration. This section, based on bionic principles, proposes to enhance the mechanical properties of the collagen membrane with silk fibroin to achieve synergistic regeneration of periodontal bone\u002Fsoft tissue. This project employs silk fibroin-reinforced collagen membrane technology to overcome the dual bottlenecks of insufficient strength and excessively rapid degradation of existing materials; establishes a \"structure-guided, mechanically supported, factor-controlled release\" trinity regeneration strategy to achieve precise repair of periodontal composite tissues. This study will provide new materials and methods for periodontal regeneration and offer a theoretical reference for the combined regeneration of other hard\u002Fsoft tissues.",[28],[57,58,59,60],"Alveolar bone","Collagen","Silk fibroin","Membrane material","2026-05-03",{"date":63,"type":37},"2026-05-08",{"date":39,"type":21},{"date":41,"type":21},{"name":43,"class":44},{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":85,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100619052","flapless-periodontal-regeneration-using-hyaluronic-acid-versus-enamel-matrix-derivative-100619052","NCT07339605","Flapless Periodontal Regeneration Using Hyaluronic Acid Versus Enamel Matrix Derivative","Clinical and Radiographic Outcomes After Flapless Approach of Intrabony Defects With the Application of Enamel Matrix Derivative Versus Hyaluronic Acid: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* Periodontitis stage III or IV, grade A or B (Tonetti et al., 2017): attachment loss ≥ 5mm, radiographic bone loss extending to to the middle third and beyond, tooth loss ≥4 due to periodontitis, probing depth (PD) ≥ 6mm.\n* Older adults ≥ 18 years. The number per sex shall be balanced.\n* Plaque index (PI) \\\u003C 1 following initial periodontal therapy and hygiene instructions.\n* Bleeding on probing (BoP) ≤ 10%.\n* Only patients with optimal compliance, assessed during etiological therapy, will be selected.\n* At least a 2-3 wall interproximal bone defect with a radiographically moderate or deep intrabony defect (≥3mm), PD≥ 6mm using a Williams probe on uniradicular teeth or mandibular molars without furcation involvement after non-surgical periodontal treatment.\n* Vital teeth or teeth with well-performed root canal treatment.\n* Absence of caries, prosthetic restoration or periapical infection in the tooth to be regenerated.\n* Absence of systemic pathology.\n* Negative history of pregnancy.\n* Signed informed consent.\n* The participant is willing and able to comply with the necessary visits for the treatments and evaluations scheduled during the clinical study.\n\nExclusion Criteria:\n\n* The participant is pregnant, breastfeeding or plans to become pregnant in the next 6 months.\n* Smoking ≥10 cigarettes\u002Fday.\n* Daily alcohol intake \\> 4U.\n* Chronic illness or reduced mental capacity that may influence compliance with the protocol.\n* Medications or drugs that alter the patient's healing or with concomitant oral manifestations that, in the opinion of the investigator, could interfere with the assessment of safety or efficacy.\n* Systemic diseases that may influence treatment such as diabetes mellitus or rheumatoid disease.\n* Allergies to drug compounds.\n* Antibiotic intake 3 months prior to the start of the study or systemic condition requiring antibiotic coverage at the time of periodontal treatment.\n* Periodontal treatment 6 months prior to the start of the study.",{"count":75,"type":21},60,[24],"The goal of this clinical trial is to radiographically assess the effectiveness of minimally invasive non-surgical technique (MINST) combined with local administration of sodium hypochlorite gel (Perisolv®) and 1.6% cross-linked hyaluronic acid (HA, Hyadent BG®) compared to a neutral formulation of EDTA (Prefgel®) and enamel matrix derivative (EMD, Emdogain® FL) in periodontal regeneration. The main questions it aims to answer are:\n\n* ¿Does the combination of MINST with the local administration of sodium hypochlorite gel and 1.6% cross-linked hyaluronic acid show a potential for periodontal regeneration similar to evaluating clinical and radiographic variables compared to a neutral formulation of EDTA and enamel matrix derivative?\n* ¿What is the patient perception and satisfaction with the received treatment?\n\nResearchers will compare A (MINST with Perisolv® + Hyadent BG®), B (MINST with PrefGel® + Emdogain® FL) and C(MINST without any bioactive product).\n\nThe sample will be distributed according to the following treatments:\n\n* Experimental group: Scaling and root planing (SRP), MINST with Perisolv® + Hyadent BG®.\n* Active comparator group: SRP, MINST with PrefGel® + Emdogain® FL.\n* Control group: SRP, MINST without any bioactive product.\n\nPatients will be screened by a first visit in which they will be assigned their periodontal status. If they meet the eligibility criteria, they will be treated according to the EFP clinical guideline for periodontitis treatment: step I and step II.If the periodontal defect persists at the 12-week re-evaluation, patients will be randomised to treatment A, B or C.\n\nAfter the intervention, all participants will be checked weekly for the first 6 weeks to remove accumulated plaque, and every 3 months for 1 year. Periodontal parameters will be re-evaluated 6 and 12 months after periodontal regenerative intervention.",[79,80,28,81,82,83,84],"Guided Tissue Regeneration, Periodontal \u002F Methods","Dental Enamel Proteins* \u002F Therapeutic Use","Hyaluronic Acid* \u002F Therapeutic Use","Humans","Intrabony Defect","Flapless",[27,86,87,88,89],"Intrabony defect","Hyaluronic acid","Enamel matrix derivative","Periodontal regeneration","RECRUITING","2026-01-04",{"date":93,"type":37},"2026-01-14",{"date":95,"type":37},"2024-10-26",{"date":97,"type":21},"2027-07",{"name":99,"class":44},"University of Valencia",1]